ICH Guidelines for the Assessment of Herbal Drugs

• The International Conference on Harmonisation (ICH) provides guidelines for evaluating the quality, safety, and efficacy of herbal drugs.
• These guidelines help harmonize regulatory requirements across different regions.

Objectives:

• Establish a harmonized regulatory framework for herbal drugs.
• Provide guidance on assessing active pharmaceutical ingredients (APIs) of herbal origin.
• Standardize procedures for clinical evaluation of herbal medicines.
• Recommend approaches for preclinical safety evaluation.
• Identify and address potential public health risks.

Key Aspects of Assessment:

1. Quality Assessment

   • Evaluates physical, chemical, and biological
   • Uses macroscopic, microscopic, organoleptic, and chromatographic

2. Safety Assessment

   • Assesses toxicological profile using acute, sub-acute, chronic toxicity, genotoxicity, and carcinogenicity

3. Efficacy Assessment

   • Examines therapeutic properties using pharmacological and clinical tests such as animal models, human trials, and systematic reviews.

4. Standardization

   • Establishes specifications for plant materials and finished products.
   • Uses reference standards, marker compounds, and chemical fingerprinting.

5. Manufacturing

   • Ensures compliance with Good Manufacturing Practices (GMP) for herbal drug preparation and processing.

Key ICH Guidelines by Category:

1. Quality Guidelines (Q):

   • Ensure product quality. Key guidelines:
     • Q1A (R2): Stability Testing of New Drug Substances and Products
     • Q2 (R1): Validation of Analytical Procedures
     • Q3A (R2): Impurities in New Drug Substances
     • Q5A (R1): Viral Safety Evaluation for Biotechnology Products

2. Safety Guidelines (S):

   • Ensure drug safety. Key guidelines:
     • S1A: Need for Carcinogenicity Studies
     • S2 (R1): Genotoxicity Testing
     • S5 (R3): Toxicity to Reproduction and Male Fertility

3. Efficacy Guidelines (E):

   • Ensure therapeutic efficacy. Key guidelines:
     • E3: Structure and Content of Clinical Study Reports
     • E6 (R2): Good Clinical Practice
     • E9: Statistical Principles for Clinical Trials

4. Multidisciplinary Guidelines (M):

   • Cover cross-category aspects. Key guidelines:
     • M3 (R2): Nonclinical Safety Studies for Human Clinical Trials and Marketing Authorization
     • M7 (R1): Control of DNA Reactive (Mutagenic) Impurities

Click Here to Watch the Best Pharma Videos